Page 3 - Executive Albert Bourla News Today

By Michael Erman (Reuters) - More than 2.8 million courses of Pfizer Inc's COVID-19 oral antiviral treatment Paxlovid have been made available at phar...

More than 2.8 million courses of Pfizer Inc s COVID 19 oral antiviral treatment Paxlovid have been made available at pharmacies around the United Stat...

As Paxlovid has become more widely used, some patients have reported that COVID-19 symptoms recurred after completing treatment.

More than 2.8 million courses of Pfizer Inc’s COVID-19 oral antiviral treatment Paxlovid have been made available at pharmacies around the United States, with…

Pfizer Inc maintained sales forecasts for its pandemic products on Tuesday after a series of hikes to revenue projections for its COVID 19 vaccine las...

Pfizer forecast more than $50 billion in 2022 sales for its Covid-19 vaccine and therapeutic on Tuesday as the pharmaceutical giant reported a more than doubling of annual profits on strong sales of its innoculation

Chief Executive Albert Bourla says 2021 was a 'watershed year' for drugmaker, with its efforts during the pandemic 'fundamentally changed our company forever'

NEW YORK - Pfizer forecast more than $50 billion in 2022 sales for its Covid-19 vaccine and therapeutic on Tuesday as the pharmaceutical giant reported a more than doubling of annual profits on strong sales of its innoculation.

Pfizer forecast more than $50 billion in 2022 sales for its Covid-19 vaccine and therapeutic on Tuesday as the pharmaceutical giant reported a more than doubling of annual profits on strong sales of its innoculation.

Pfizer forecast more than $50 billion in 2022 sales for its Covid-19 vaccine and therapeutic on Tuesday as the pharmaceutical giant reported a more than doubling of annual profits on strong sales of its inoculation.